CSPG4 and melanoma: In contrast to the GBM xenografts, NG2 shRNA treatment may have drastically reduced neovascularisation in the melanoma tumours, thereby cutting off oxygenation and nutrient supply resulting in apoptosis and arrested cell cycle progression.